Looking forward to it @drhungo !!!

#ESCCongress2024 done 👏🏻 👏🏻 Gearing up for Brisbane GPCE ✈️ to talk Lipids & cardiovascular risk with good friend & colleague @ajnelson Conference link/discount below 👇🏼 Code SPEAKER50ADV to get 50% off your Conference Pass. #GPCEBrisbane

Results of the CAMERA-MRI II study LBCT #ESC2024: catheter ablation in AF and LVSD with LV fibrosis superior to medical therapy with respect to LVEF improvement, functional status, patient symptoms and reverse LA remodeling @ESCardioNews @drjohnm @peterkistler3 @drsunnyprabhu

Excited to launch @TheLancet Commission on Finding Solutions for the Cardiovascular Disease Burden in the Asia Pacific Region with my good friend @lamcardio - a lot of work lies ahead with energetic colleagues @richardhorton1 @dukenus @MonashVHI

Thrilled to present the results from the WITHDRAW-AF randomized clinical trial at #ESC2024 - low LVSD relapse rates in recovered AFCM following withdrawal of HF pharmacotherapy @BakerResearchAu @UniMelb @AlfHeartCentre @escardio @drjohnm

Loss of kidney function accelerates dramatically after HF, while atherosclerotic & HF risk increases 3-4 fold after CKD progression Highlighting epidemiological & therapeutic synergies between CKD & CV disease Cardio-kidney-metabolic #simpub for #ESCCongress in @JACCJournals

Patients with HFrEF have ⬆️ incident cancer but undergo ⬇️ cancer screening than the general population (despite expressing interest). Should we include cancer screening in HFrEF programs? https://t.co/7ZQaYJjgX4 #cardiooncology #reversecardiooncology @MonashVHI

Fantastic work by @cardiopharmnerd - discharge pathways post PCI and CABG look different but use of secondary prevention medications should be similar… plenty of opportunities to improve adoption of evidence based therapies.

Thanks for the opportunity @ProfSNicholls & @lamcardio ... Despite housing 60% of the global burden of CVD, our earlier work has shown that < 10% of participants enrolled in seminal cardiometabolic studies are from APAC. Huge opportunities @the_apcmc https://t.co/wkPNUIedID

REGISTER: https://t.co/PPmbKQl3bp A MDT panel presents the latest updates on the use of disease-modifying treatments in cardio-renal metabolic disease and discusses models of care for improved patient outcomes. @brendonneuen @KrishRathika @ajnelson @DrSarahGlastras @ANZSN

Many practical challenges affect ASCVD prevention in patients with cancer treated immunotherapy. Huge scope for opportunistic screening and implementation research in #CardioOncology @ProfSNicholls @profevasegelov @ajnelson @MonashVHI @ESC_Journals https://t.co/Pwqo822Hdl

Happy to inform our “remote follow-up in #PragmaticTrials” at #ACC has #SimPub to @JCardFail. Thanks for the team and mentorship from @_adevore @DukeCardFellows @DCRINews @robmentz @gcfmd @JavedButler1 @kofi_larry @DukeHFDoc @FudimMarat @ajnelson @texhern https://t.co/19GCZT1Zx4

Great to have @SJGreene_md all the way from @DCRINews here in Adelaide @thecsanz reminding us of the importance of simultaneous commencement & rapid titration of HFrEF therapies. Incredible body of work highlighting gaps and importantly a path forward! @lamcardio

Great to have @WongChrisX back in town kicking off @SAHMRI_Heart emerging leaders symposium. Translational data linking dietary factors with propensity for arrhythmia. @UniofAdelaide @Elliott_AD @PrashSanders @ChrisBursill

Excellent summary of the renal benefits SGLT2 inhibitors by ⁦@SantosGallegoMD⁩ at #ADA2023 ⁦@JavedButler1⁩ ⁦@hvanspall⁩ ⁦@ajnelson⁩ ⁦@MWilkinsonMD⁩ ⁦@MountSinaiHeart⁩

Patients receiving immune checkpoint inhibitors for cancer routinely have their BP checked when they attend for treatment. Could we be repurposing this for hypertension screening? https://t.co/guKmdduDoN @ProfSNicholls @ajnelson @profevasegelov @MonashVHI #CardioOncology

Thanks to Sreek Vemulapalli for his leadership, and to Sean O'Brien and Dianne Gallup for their tireless statistical support @DCRINews, as well as a village of supportive coauthors, some of whom are on twitter...@djc795 @ajaykirtane @NimeshDesaiMD @ericpetersonMD

Our study has limitations. We used simulations and adjusted models including a number of assumptions such as constant site-level outcomes despite increased modelled capacity. Notwithstanding these, we hope our work stimulates discussion in the evidence-based policy space.

Mitigating the population-to-patient tension of equitable access, market-driven expansion, training capacity & high quality outcomes for TAVI patients remain complex and important considerations for payers, health systems & policy makers.

Instead, leveraging spoke-and-hub models, or incentivizing network-based approaches where high-performing sites support low-performing sites (rather than using volume as a proxy) may be a more effective way at achieving the best TAVI outcomes nationally.